Journal
IMMUNOTHERAPY
Volume 12, Issue 8, Pages 555-561Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/imt-2019-0100
Keywords
intrahepatic cholangiocarcinoma; microsatellite instability; MSI; Phase I; PD-1; programmed cell death 1 inhibitor; TMB; tumor mutation burden
Categories
Funding
- Innovent Biologics
Ask authors/readers for more resources
Intrahepatic cholangiocarcinoma is a disease with grave prognosis due to limited therapeutic regimens. Programmed cell death 1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitor have shown dramatic clinical effectiveness in multiple solid tumors. Here, we report the case that a patient with metastasis intrahepatic cholangiocarcinoma, being failure of first-line chemotherapy, was enrolled into the Phase I study of a PD-1 inhibitor, sintilimab. The patient achieved complete remission after three cycles of treatment with mild adverse reaction. In addition, the tumor mutational burden and the microsatellite instability status were low in the present case. Hence, PD-1 inhibitor might be a promising therapeutic approach for patients with advanced cholangiocarcinoma.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available